Evercore ISI downgraded Bellus Health (BLU) to In Line from Outperform with a price target of $14.75, down from $24, after the company agreed to a deal to be acquired by GSK (GSK).
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BLU:
- GSK to acquire Bellus Health for $14.75 per share
- Bellus Health Surges after Acquisition by GSK for $2 Billion
- Bellus Health management to meet with Piper Sandler
- Bellus Health announces results from camlipixant bioavailability study
- Bellus Health reports FY22 EPS (66c), consensus (70c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue